Stock Analiz

KORU Medical Systems, Inc. KRMD

Medical/Dental Instruments · data as of November 13, 2026

$3.70Market cap $160M
Open the interactive analysis →

KORU Medical Systems, Inc. (KRMD) is a healthcare company listed in the US with a market value of about $160M. In the twelve months to September 30, 2026 it had revenue of $46M and net income of -$823382, a net margin of -1.8%.

Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 11% a year, a 5-year average ROIC of -22%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 83% below the current price.

About KORU Medical Systems

KORU Medical Systems is listed in the US and classified in medical/dental instruments. Revenue went from $11M in 2015 to $41M in 2025, growth of about 13.8% a year. It was profitable in 3 of the last 10 years in our data. Its share count rose by 3% over three years (dilution for shareholders). It spends 11% of revenue on research and development.

Score: 1.4 / 5

Value0/5
Future growth4/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S3.5
P/B8.3
EV/EBITDA786.8
PEG—
Dividend yield0.00%
FCF yield-0.2%
Shareholder yield0.0%
Intrinsic value vs. price−83%

Growth and quality

Revenue growth (1 yr)22.2%
Revenue growth (5 yrs, per year)11.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-24.6%
ROIC (5-yr avg.)-21.6%
Profitable years (of last 10)3
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$46M$41M$34M$29M$28M$23M$24M$23M$17M$12M$12M
Net income-$823382-$3M-$6M-$14M-$9M-$5M-$1M$564349$910570-$534999$782864
Free cash flow-$387369-$470112-$2M-$6M-$8M-$5M-$2M$119446$1M-$534741$2M
EPS (diluted)$-0.02$-0.06$-0.13$-0.30$-0.19$-0.10$-0.03$0.01$0.02$-0.01$0.02
Net margin-1.8%-6.4%-18.0%-48.2%-31.1%-19.4%-5.0%2.4%5.2%-4.3%6.4%
ROIC—-11.5%-24.9%-33.3%-24.5%-13.6%-2.7%4.1%10.1%-7.6%11.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is KORU Medical Systems stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 83% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does KORU Medical Systems pay a dividend?

Not currently.

Is KORU Medical Systems a good stock to buy?

We do not give buy or sell advice. KORU Medical Systems scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.